Reubi J C, Laissue J A
Division of Cell Biology, University of Berne, Switzerland.
Trends Pharmacol Sci. 1995 Mar;16(3):110-5. doi: 10.1016/s0165-6147(00)88992-0.
The role played by the neuropeptide somatostatin, also known as somatotropin release inhibitory factor (SRIF), in human cancer is not well understood. Recent investigations involving somatostatin receptors in normal and neoplastic human tissues suggest that the action is complex and involves both direct and indirect mechanisms. In this article, Jean-Claude Reubi and Jean Laissue describe the variety of biological mechanisms involved in neoplasia that are associated with somatostatin, and illustrate the therapeutic potential and present limitations of somatostatin analogues.
神经肽生长抑素，也称为生长激素释放抑制因子（SRIF），在人类癌症中所起的作用尚未得到充分了解。最近对正常和肿瘤性人类组织中生长抑素受体的研究表明，其作用是复杂的，涉及直接和间接机制。在本文中，让 - 克洛德·勒比和让·莱西描述了与生长抑素相关的肿瘤形成中涉及的多种生物学机制，并阐述了生长抑素类似物的治疗潜力和目前的局限性。
